The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus

DOI: 10.1186/s12933-019-0869-2

Keywords: Diabetes mellitus, Major adverse cardiovascular event, Sodium glucose co-transporter 2 inhibitor, Canagliflozin

Full-Text   Cite this paper   Add to My Lib

Abstract:

Renal actions of SGLT2 inhibitors. SGLT2, sodium glucose co-transporter 2; SGLT1, sodium glucose co-transporter

Full-Text